Stockscreener 앱 받기
9.34
1.74%
0.16
시간 외 거래:
9.36
0.02
+0.21%
Viatris Inc 주식(VTRS)의 최신 뉴스
Andrew Smith Reports 2.90% Stake In Smarter Web Company As At June 13 Vs Prior Stake Of 10.39% - MarketScreener
Psoriasis Biosimilars Market Key Players Analysis- Merck KGaA, - openPR.com
Viatris Inc’s Mixed Bag: Down -29.49% in 6 Months, Down 2.28% in 30 Days - investchronicle.com
3 Reasons to Avoid VTRS and 1 Stock to Buy Instead - Yahoo Finance
Viagra ‘Make Love Last’ wins Pharma Grand Prix after artfully working around Chinese ad regulations - Ad Age
ViatrisMAKE LOVE LAST59s - Ad Age
Viatris to Report Second Quarter 2025 Financial Results on August 7, 2025 - BioSpace
Viatris Announces Q2 2025 Earnings Call: Key Details for Investors Released - Stock Titan
Is Viatris Inc (VTRS) Set to Underperform? Analyzing the Factors Limiting Growth - GuruFocus
Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Viatris - sharewise
Teva, Amneal rated Buy, Viatris Neutral as Goldman Sachs reviews generics space - MSN
Transcript : Viatris Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 10 - marketscreener.com
Goldman Sachs Initiates Coverage of Viatris (WBAG:VTRS) with Neutral Recommendation - Nasdaq
Goldman Sachs Initiates Coverage of Viatris (VTRS) with Neutral Recommendation - Nasdaq
Viatris (VTRS) Faces Securities Fraud Class Action Over FDA Inspection Fallout - Insider Monkey
Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris? - Benzinga
Goldman Sachs Initiates Coverage on Viatris (VTRS) with Neutral Rating | VTRS Stock News - GuruFocus
Goldman Sachs starts Viatris stock coverage with neutral rating - Investing.com
Transcript : Viatris Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-05-2025 08 - marketscreener.com
Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals And Viatris - Barchart.com
June 3, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against VTRS - TradingView
Class Action Lawsuit Filed: Viatris Inc. (VTRS)Join by June 3, 2025Contact Levi & Korsinsky - ACCESS Newswire
Viatris Deadline Today: Rosen Law Firm Urges Viatris Inc. (NASDAQ: VTRS) Stockholders With Large Losses to Contact the Firm for Information About Their Rights - Business Wire
VTRS Investors Have Opportunity to Lead Viatris Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
Viatris Inc (VTRS)'s Uncertain Future: Understanding the Barriers to Outperformance - GuruFocus
VTRS Investors Have the Opportunity to Lead the Viatris Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - StreetInsider
June 3, 2025 Deadline Approaching: Join Class Action Against Viatris Inc. (VTRS)Contact Levi & Korsinsky - ACCESS Newswire
Viatris (VTRS) Reports Positive Phase 3 Trial Results for Night Driving Treatment - GuruFocus
Viatris sees positive top-line phase 3 results for night driving impairment asset - Seeking Alpha
VTRS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
VTRS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Viatris Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris - GlobeNewswire
June 3, 2025 Deadline: Join Class Action Lawsuit Against Viatris Inc. (VTRS)Contact Levi & Korsinsky - ACCESS Newswire
Viatris Inc. (VTRS) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Viatris Inc. of Class Action Lawsuit and Upcoming DeadlinesVTRS - FinancialContent
Viatris reports success in phase 3 trial of night vision treatment MR-142 - Investing.com India
Viatris (VTRS) Reports Positive Results from LYNX-2 Trial for Eye Treatment | VTRS Stock News - GuruFocus
VTRS STOCK DEADLINE TOMORROW: Suffer Losses on Viatris - GlobeNewswire
Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions - PR Newswire
Shareholders of Viatris Inc. (VTRS): Protect Your Rights Before June 3, 2025Contact Levi & Korsinsky - ACCESS Newswire
Class Action Filed Against Viatris Inc. (VTRS)June 3, 2025 Deadline to JoinContact Levi & Korsinsky - PR Newswire
VTRS DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, - GlobeNewswire
VTRS DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Viatris Inc. Investors with ... - Bluefield Daily Telegraph
VTRS DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Viatris Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action – VTRS - TradingView
Viatris Deadline: VTRS Investors with Losses in Excess of $100K Have Opportunity to Lead Viatris Inc. Securities Fraud Lawsuit - The Malaysian Reserve
Lost Money on Viatris Inc. (VTRS)? Urged to Join Class Action Before June 3, 2025Contact Levi & Korsinsky - ACCESS Newswire
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris - StreetInsider
Did You Lose Money on Viatris Inc. (VTRS)? Levi & Korsinsky Urges Investors to Act Before June 3, 2025 - Stockhouse
VTRS CLASS NOTICE: Viatris Inc. Investors may have been - GlobeNewswire
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris - marketscreener.com
VIATRIS 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Viatris Inc.VTRS - Business Wire
Deadline Soon: Viatris Inc. (VTRS) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - Business Wire
Viatris Inc. Securities Fraud Class Action Lawsuit Pending: - GlobeNewswire
1.09%
0.40%
자본화:
|
볼륨(24시간):